Prognostic Biomarkers in Predicting Mortality in Respiratory Patients With Ventilator-Associated Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

136 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-06

Study Completion Date

2019-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate prognostic efficiency RDW and NLR for mortality prediction in respiratory patients with VAP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictors of Mortality Among Ventilator Associated Pneumonia Patients

NCT06246994

Pneumonia

NOT_YET_RECRUITING

Diagnostic Modalities for VAP Detection

NCT04911244

Ventilator Associated Pneumonia

COMPLETED NA

Risk Factors of Ventilator-Associated Pneumonia in Critically Ill Population of Alexandria

NCT07116382

Ventilator Associated Pneumonia

COMPLETED

A Study on Ventilator-associated Pneumonia as a Risk for Nosocomial Infection in Mechanically Ventilated Neonates In NICU of Assiut University Children Hospital (Nicu Eta)

NCT03310840

Neonatal SEPSIS Nosocomially Acquired Neonatal Sepsis

COMPLETED

Lung Ultrasound in Procalcitonin- Guided Antibiotic Discontinuation in Ventilator Associated Pneumonia

NCT04563104

Ventilator Associated Pneumonia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ventilator-associated pneumonia (VAP) is the most common nosocomial infection. VAP continues to be a leading cause of morbidity and mortality in the nosocomial setting. Red cell distribution width (RDW) and neutrophil-lymphocyte ratio (NLR) are prognostic factors to mortality in different diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventilator Associated Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Respiratory ICU patient

patient in RICU that developed ventilator-associated pneumonia

complete blood picture

Intervention Type DIAGNOSTIC_TEST

Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

complete blood picture

Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Respiratory failure needs mechanical ventilator support \> 48 hrs. VAP was defined as an acute lower respiratory tract infection in mechanically ventilated patient \> 48 hrs with a new or progressing infiltrate on chest radiograph and who met at least two of the following clinical criteria: body temperature \>38°C or \<36°C with no other recognized cause, white blood cell count \>10,000 /mm3 or \<5000 /mm3, or a macroscopically purulent tracheal aspirate
* Only the first VAP episode was included

Exclusion Criteria

* Neutropenia (\< 500 cells/ml) before the development of VAP.
* Conditions are known to influence total and differential WBC counts such as chronic inflammatory conditions, hematologic disorders, history of chemotherapy, or radiotherapy within 4 weeks before enrollment.
* Conditions are known to affect RDW as anemia due to nutritional deficiency (ie, iron, vitamin B12, and folic acid).
* Patients with HIV/AIDS

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No